Why the study?
Heart failure and diabetes are increasing in prevalence, prompting a review of current heart failure therapies and newer glucose-lowering drugs in patients with or at risk for heart failure.
Newer glucose-lowering medications provide significant cardiovascular and heart failure benefits for patients with and without diabetes.
Supports broader consideration of newer T2D agents in HF; leaves open optimal sequencing and real-world durability.
Both heart failure and diabetes are increasing in prevalence in Western communities. The interrelationship between these two conditions is well known, with conventional heart failure therapies including several newer drug classes providing benefit to subjects with diabetes. Furthermore, several of the more recently introduced medications for type 2 diabetes have resulted in significant cardiovascular morbidity and mortality benefits with a marked improvement in heart failure symptoms and hospital presentations as well as deaths. This review outlines current therapies used to treat patients with or at risk for heart failure and their particular role in subjects with diabetes. Newer therapies, including certain glucose-lowering medications and their benefits in treating heart failure patients with and without diabetes, are also discussed. Finally, heart failure is also observed in long-duration, aging patients with type 1 diabetes, but this clinical issue has not been as extensively explored as in patients with type 2 diabetes and warrants further clinical investigation.
No takes yet. Share an insight, caveat, or question.
Shaw et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: